CICC released a report last Friday (December 31) setting out the investment ratings and target prices of traditional Chinese medicine and mainland pharmaceutical stocks:
Target price of "investment rating" for shares (HK $)
Baiyunshan (00874.HK) "outperforms the industry" 25 yuan
Tongrentang Technology (01666.HK) "outperforms the industry" 7.1yuan
Guorentang traditional Chinese Medicine (03613.HK) "outperforms the industry" 13.3 yuan
Chinese traditional medicine (00570.HK) "outperforms the industry" 5.05 yuan
Alibaba Health Information Technology (00241.HK) "outperforms the industry" 10.9 yuan
JD Health (06618.HK) "outperforms the industry" 102.4 yuan
China Resources Pharmaceutical (03320.HK) "outperforms the industry" 5.42 yuan
------------------------------------------------------
Stock market forecasts price-to-earnings ratio for 2022
Baiyun Mountain is 7.5 times as much as it is.
Tongrentang Technology Co., Ltd. 13.8 times
The medicine of Guorentang is 14.7 times.
9.7 times of Chinese traditional medicine
China Resources Pharmaceutical Co., Ltd. 5.1 times
Correction: 2022-01-03 15:07:36 "Big Bank report" CICC's investment rating and target price on traditional Chinese medicine and pharmaceutical stocks (table)